Biotechnology in Switzerland

Acm Biosciences Ag

ACM Biosciences AG was established in Basel, Switzerland in September 2020. It is dedicated to the development of infectious disease vaccines using it's proprietary ACM polymersome platform technology. Its current primary focus is to get a safe, effective and highly manufacturable COVID-19 vaccine through clinical trials.

11 to 50 staff

Alithea Genomics

RNA sequencing at scale.

11 to 50 staff

Kbiotech Gmbh

Kbiotech is a company rooted in the Swiss culture of innovation driven by the passion of experts who, for more than 20 years, have been working in the biotechnology, medical, pharmaceutical and renewable energy sectors. A team of competent, motivated people with a common goal: to find the best solution for their customers. We specialize in customized solutions and our strength is absolutely the customer. Kbiotech develops, manufactures and markets laboratory instruments and equipment up to the complete production of bioreactors and fermenters.

11 to 50 staff

Pb&b

PB & B Ltd. is a specialty Swiss Life Sciences company founded by bioengineers working with plastic surgeons & dermatologists to test and bring to market a new patented injectable technology for the remodeling of soft tissues of the face & body. PBB-002 enhances adipocytes' volume with fatty acids, as to provide natural & longer-term results with the highest level of safety. PB & B’s patented technology aims to transform a fast growing, multi-billion-dollar facial aging & body remodeling markets with the next generation of injectables in Medical Aesthetics.

1 to 10 staff

Swiss Biotech Center

The Swiss Biotech Center is non-for-profit, self-sustained company, acting as a competence center in Life Sciences open to innovative companies and academic researchers and developers. Our offer spans two complimentary domains- In-Vitro Diagnostics, with a specific focus on Point-Of-Care Tests (POCT)- Biopharmaceuticals. We provide customized services of development, a top-notch laboratory and infrastructure, including a cGMP compliant clean room for the Biopharmaceutics activity and a lab dedicated to lateral flow technology. In addition, Swiss Biotech Center has assembled an extensive network of partners to help our customers developing the new life sciences products and technologies that will shape our future. Located in Monthey, in the canton of Valais in Switzerland, we are at the heart of the Swiss “Health Valley”.

1 to 10 staff

Genomed

Genomed is committed to developing and adapting leading edge technology to application solutions for molecular diagnostic laboratories. Over 20 years’ experience in the fields of Clinical Genetics and DNA based Forensics testing has resulted in an extensive company knowledge base, putting Genomed at the forefront of these technologies. The company has two divisions: • The development, manufacture and distribution of molecular diagnostic tests • Establishing complete Turn-Key Molecular Laboratories

11 to 50 staff

Jawslab

Jawslab is a digital assistant that facilitates the organization and transmission of scientific data to increase reproductibility of results

1 to 10 staff

Abiotec Ag

Customer-specific Pharma-projects covering Upstream and Downstream of Biopharmaceuticals, including Formulation Technology. According to Quality by Design (QbD) standards of the ICH, we support our customers to gain profound process understanding, leading to well-designed and controlled processes with a proven transferability throughout the scales from R&D to Production. Working focus since 2013 on Consulting and Interim-Management for big Pharma and MedTech companies: Biopharmaceuticals, Projects with focus on Quality aspects: Upstream Processing (USP), Downstream Processing (DSP), Fill & Finish Parenteralia, Quality supporting processes, Technology Transfer, Projects following Quality by Design (QbD), A-Mab-Case Study from CMC Biotech Working Group

1 to 10 staff

Achiko

Achiko AG (SIX: ACHI.SW) is developing disruptive diagnostic solutions that puts people first. Invented by Dr Michael Edel, the company’s flagship product is a fast, friendly, affordable and accurate Covid-19 test with a companion app. The test and companion app were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX™ and companion health apps via its digital mobile health technology division, Teman Sehat™. The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX™ and Teman Sehat™, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field. Headquartered in Zurich, Achiko has offices in Jakarta and Singapore.

11 to 50 staff

Acthera Therapeutics Ltd

ACTHERA was a Swiss biotech company founded in 2019, in liquidation since 2024. The team was developing a therapeutic platform based on a unique type of liposomes for the targeted delivery of drugs. Due to lack of funding, the decision was taken early 2024 to liquidate the company.

1 to 10 staff

Amphilix Ag

Amphilix AG is a Basel, Switzerland based biotech making bifunctional molecules to treat complex diseases using a proprietary linker platform. The linkers employ sophisticated 3D elements which allows the optimization of physicochemical and pharmacokinetic properties. Our lead project is a new First-in-Class targeted radioligand therapy for cancer for which we have teamed up with the Center of Radiopharmaceutical Sciences at the Swiss Federal Institute of Technology (ETH Zürich). Amphilix' drug target is highly expressed in cancer cells and in tumor-associated growing blood vessels and we have demonstrated selective uptake of our radioligand AMX-0053 within a mouse tumor model. The choice of target and use of the proprietary linker platform to optimize the radioligands fully differentiates Amphilix' product from those of other companies.

1 to 10 staff

Astra Therapeutics

At ASTRA Therapeutics, we are redefining parasite drug development by leveraging the specificity of Parabulins™. Our mission is clear: to lead the fight against parasitic diseases with precision-engineered solutions.

1 to 10 staff

Avrion Therapeutics

Avrion Therapeutics is a spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL) developing innovative precision gene therapies for neurodegenerative disorders. Avrion’s approach is based on cell-type specific vector-based solutions to target discrete Central Nervous System (CNS) cell populations. This results in synergistic neuroprotection, while simultaneously enhancing safety. Avrion’s first gene therapy candidates target Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease (MND). Investigation of ALS pathogenic mechanisms has mostly been focused on motor neurons so far. However, emerging evidence supports that non-neuronal cells (i. e. astrocytes, microglia) play a critical role in the disease, through reshaping neuronal synaptic connections. To address this pathology, Avrion has engineered two candidate gene therapy products referred to as AVR-001 and AVR-002. The first candidate (AVR-001) harnessed an advanced vector platform designed to selectively and simultaneously target ALS associated with mutations (or pathogenic misfolding) of SOD1 in both neurons and astrocytes. AVR-001 has been validated as potently effective and safe in both rodent and non-human primate models. Our second candidate gene therapy product (AVR-002) addresses all forms of ALS. AVR-002 is designed to engage a novel neuroimmune pathophysiological mechanism which occurs in both familial and sporadic forms of ALS, plus potentially other neurodegenerative disorders (like frontotemporal dementia). This wholly novel disease mechanism emerged from a suppressor screen using our discovery platform, which exploits humanized Drosophila as disease models. The uniqueness of AVR-002 therapeutic solution is to combine (i) vector-based targeting of glial cells, and (ii) protein engineering to deliver a cell-type selective neuro-immunomodulatory factor that can protect neuronal synaptic connections in ALS.

1 to 10 staff

Biogecho

Drug Development Strategy and International Regulatory Affairs. Strategic advice on clinical development and on registration of medicinal products, i.e. pharmaceutical, biotech products, ATMPs, orphan drugs, vaccines, generics, biosimilars and medical devices. Biogecho supports also Pharmaceutical Small and Medium Enterprises (SMEs) in their establishment in Europe and Switzerland.

1 to 10 staff

Dna Essence

DNA Essence develops innovative DNA based ingredients for the beverage industry and other industries. The DNA is produced artificially using biotechnological methods, so that our product offers a possibility to obtain the necessary ingredients with no harm to animals. The use of our artificial DNA as an ingredient for beverages, food and cosmetics is protected by a recently filed patent application. DNA Essence is looking for partners from the beverage industry to realize beverage products with artificial DNA especially of wild animals, like sharks, rhinos or tigers. In such a partnership, DNA Essence will develop and produce customized formulations of DNA which can be added to all kinds of beverages. DNA Essence can also grant licenses to beverage producers, if they prefer to develop and produce the DNA formulations internally.

1 to 10 staff

Healiva

Healiva`s mission is to heal life, by offering a portfolio of innovative acute and chronic wound care solutions, which are personalized and affordable. Our approach combines enzyme technology, cell therapies and medical devices. We offer end-to-end offering of wound care solutions. Our multi-pronged approach to become the go-to-provider for all wound care needs – from wound debridement to treatment of severe wounds. 2-3% of the elderly suffer from painful venous/arterial leg ulcers and nearly 25% of diabetics may develop diabetic foot ulcers in their lifetimes. This figure set to rise with the increasing prevalence of contributing factors, including diabetes, advanced age, and obesity. This burden is also borne by healthcare systems, which spend 2% of their budgets on wound management. About ≈60% of chronic wounds remain unhealed. There remains a major gap in the current treatment paradigm. No permanent therapy for non-healing wounds currently exists. A successful regimen can prevent osteomyelitis, hospitalisation, amputation, and even death, allowing patients to re-establish their normal work/life routines. Healiva is targeting key pain-points in the patient care pathway. Our multifaceted customer base encompasses hospitals, medical practitioners, insurance providers and patients. We are developing a unique selling proposition for chronic wounds healing targeting the high cost of care, time to heal, requirements for frequent dressing changes and specialist medical expertise, whilst reducing wounds reoccurrence and accelerating patients’ re-establishment of normal work/life routines. Healiva’s portfolio potentially address the growing un-met need for chronic wound care, which forms part of the global €15.6B wound care market.

1 to 10 staff

Lascco Sa

LASCCO SA is a Swiss-based biomedical technology company specialized in the development of discovery-stage pharmaceuticals and diagnostics. The mission of LASCCO is to validate the commercial potential of innovations stemming from universities in order to create value and bring them to the attention of industry leaders.

1 to 10 staff

Seal Therapeutics Ag

SEAL Therapeutics is developing its proprietary SEAL technology as a potential gene therapy for laminin-α2 deficient congenital muscular dystrophy (LAMA2 MD), a severe and progressive neuromuscular disease affecting children from birth. SEAL Therapeutics aims to team-up with and support a qualified pharma partner with experience in advanced gene therapy technologies for clinical development to ultimately make this innovative treatment approach available to patients.

1 to 10 staff

Therachon

Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. We are currently advancing a pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions. Our lead product candidate, apraglutide, is a second generation, potentially best-in-class, synthetic peptide analog of glucagon-like peptide-2, or GLP-2, that is being evaluated in two Phase 2 clinical trials for the treatment of patients with short bowel syndrome, or SBS, a malabsorption disorder caused by the loss of functional small intestine. Our second product candidate, TA-46, has completed a Phase 1 clinical trial and is designed to address the root molecular cause of achondroplasia, a rare genetic condition and the most common form of short-limbed dwarfism in humans. View our social media community guidelines here: http://bit.ly/2TdB4Vm.

11 to 50 staff

M-Lab Of Adaptive Intelligence

We aim to reverse engineer the neural circuits that drive adaptive motor behavior by studying artificial and natural intelligence. We design behavioral assays for mice, perform large-scale neural recordings, and build new deep learning & machine learning tools to aid in our quest of finding internal models in the brain.

1 to 10 staff

Cytos Biotechnology Ag

51 to 200 staff

Id-Gene Ecodiagnostics

ID-GENE ecodiagnostics Ltd is a Swiss company founded in 2014 as a spin-off of the University of Geneva. ID-GENE provides fast, sensitive and reliable genetic tests for environmental bioassessment and biomonitoring. We aim to empower environmental agencies, consultancies, and the industry through innovative tools for environmental impact assessment. The company works to foster scientific innovation in an entrepreneurial mindset to make environmental genomics accessible and to improve the long-term management of environmental resources. ID-GENE has developed a deep expertise in molecular ecodiagnostics. It offers comprehensive, reliable and cost-effective genetic tests to enable fast and high quality assessment of the biodiversity and environmental monitoring. ID-GENE approach is a proven reliable alternative to the traditional studies requiring specialized personnel and long time-to-result (i.e. morphology-based methods).

1 to 10 staff

Lamkap Bio Group

The core focus of this biotechnology company is in the field of research, development, and manufacturing of selected bispecific antibodies for antibody-based therapies of cancer diseases and diseases of the immune system.

11 to 50 staff

Smartgene

SmartGene is a bio-informatics application service provider (ASP), delivering secure, integrated, software solutions (SAAS) for the analysis, interpretation and data management of genetic sequences. Customers world-wide use SmartGene’s cloud-based modules for multiple applications, including HIV genotyping/resistance, HCV and Influenza analysis, bacterial and fungal identification, microbiome analysis, strain-typing and molecular epidemiology of viruses and bacteria. SmartGene provides specific medical, clinical research, industrial and epidemiological surveillance applications, designed for routine work-flows, from raw data (Sanger, NGS) to a comprehensive report. Frequently updated quality-controlled reference databases, interpretative algorithms, specifically parameterized bio-informatics tools and customized, searchable sequence databases are integrated within SmartGene’s CE-IVD labeled solutions.

1 to 10 staff